利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.028 秒)

    PREDICTIVE PERIPHERAL BLOOD BIOMARKER FOR CHECKPOINT INHIBITORS
    7.
    发明申请
    PREDICTIVE PERIPHERAL BLOOD BIOMARKER FOR CHECKPOINT INHIBITORS 有权

    公开(公告)号：US20210123920A1

    公开(公告)日：2021-04-29

    申请号：US16634833

    申请日：2018-07-27

    申请人： Bristol-Myers Squibb Company

    发明人： Nataly MANJARREZ ORDUÑO ,  Suzanne J. SUCHARD

    IPC分类号： G01N33/574 ,  A61K45/06 ,  C07K16/28

    摘要： The present disclosure relates to the finding that the ratio of circulating (i.e., peripheral blood) central memory T cells to circulating effector T cells in a cancer patient can predict whether a tumor has an inflammatory milieu or not. In addition, since having an inflammatory milieu (“hot tumor”) is a positive factor for responding to checkpoint inhibitors, e.g., PD-1 antagonists, this assay on peripheral blood can also be used to predict a response to a checkpoint inhibitor, e.g., an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or an antibody or an antigen binding portion thereof that binds specifically to PD-1 ligand 1 (PD-L1) and inhibits PD-L1 activity.

    MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH
    9.
    发明申请
    MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH 审中-公开

    公开(公告)号：US20200148779A1

    公开(公告)日：2020-05-14

    申请号：US16495994

    申请日：2018-05-24

    申请人： Bristol-Myers Squibb Company

    发明人： Aaron YAMNIUK ,  Mary STRUTHERS ,  Suzanne J. SUCHARD

    IPC分类号： C07K16/28

    摘要： Modified IgG1 Fc domains having reduced binding to Fc-gamma-receptors are provided. Further provided are fusion polypeptides comprising a modified IgG1 Fc domain. An antibody polypeptide that specifically binds a human CD40 is provided, wherein the antibody polypeptides are fusions of a domain antibody (dAb) comprising a single VH domain and an Fc domain. The antibody polypeptides do not exhibit CD40 agonist activity, do not substantially activate immature dendritic cells, and have improved biophysical properties.

    ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF
    10.
    发明申请
    ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF 有权

    公开(公告)号：US20220177596A1

    公开(公告)日：2022-06-09

    申请号：US17561529

    申请日：2021-12-23

    申请人： Bristol-Myers Squibb Company

    发明人： Aaron YAMNIUK ,  Mary STRUTHERS ,  Suzanne J. SUCHARD

    IPC分类号： C07K16/28 ,  A61K39/395

    摘要： The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.